The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MOLN | -21.39% | N/A | N/A | -76% |
| S&P | +12.65% | +91.73% | +13.89% | +59% |
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Two of them could be.
The company had some very good news to deliver about its coronavirus drug candidate.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.66M | 0.0% |
| Market Cap | $138.73M | -17.8% |
| Market Cap / Employee | $0.91M | 0.0% |
| Employees | 153 | 0.0% |
| Net Income | -$14.79M | 21.9% |
| EBITDA | -$14.25M | 11.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $131.37M | -22.8% |
| Accounts Receivable | $2.64M | -32.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.39M | -78.7% |
| Short Term Debt | $1.54M | 6.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -43.82% | -10.2% |
| Return On Invested Capital | -26.49% | 5.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$12.80M | 10.4% |
| Operating Free Cash Flow | -$12.74M | 9.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.96 | 0.92 | 0.97 | 1.04 | 0.87% |
| Price to Sales | 24.85 | 31.08 | 57.21 | 181.74 | 573.10% |
| Price to Tangible Book Value | 0.96 | 0.92 | 0.97 | 1.04 | 0.82% |
| Enterprise Value to EBITDA | -0.79 | 0.14 | -0.08 | -0.65 | 466.49% |
| Return on Equity | -33.5% | -40.4% | -48.9% | -49.9% | 33.35% |
| Total Debt | $2.70M | $2.42M | $2.31M | $1.93M | -40.87% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
